随着针对 DNA 损伤修复相关基因特定突变的患者引入 PARP 抑制剂，前列腺癌已进入精准医疗时代。最近的研究表明，与 PARP 抑制剂（如奥拉帕尼）和抗雄激素（如阿比特龙）联合治疗具有益处。这篇综述讨论了奥拉帕尼的药效学和药代动力学，以及支持奥拉帕尼和阿比特龙联合治疗的数据。共同靶向雄激素受体和 PARP 通路在治疗患有转移性去势抵抗性前列腺癌和 BRCA1、BRCA2 和 ATM 突变的患者方面显示出明显的临床益处。对于没有这些突变的患者的益处尚不清楚，奥拉帕尼联合疗法在治疗激素敏感性疾病方面的益处仍有待观察。

Prostate cancer has entered the era of precision medicine with the introduction of PARP inhibitors for patients with specific mutations in genes associated with DNA damage repair. Recent studies have shown benefit in combination therapy with PARP inhibitors like olaparib and antiandrogens like abiraterone.This review discusses the pharmacodynamics and pharmacokinetics of olaparib as well as the data supporting combination therapy with olaparib and abiraterone.Co-targeting the androgen receptor and PARP pathway has shown clear clinical benefit in the management of patients with metastatic castration resistant prostate cancer and mutations in BRCA1, BRCA2 and ATM. The benefit in patients without these mutations is less clear and the benefit of olaparib combination therapy in the management of hormone sensitive disease remains to be seen.